Progenics Form 8-K August 24, 2005
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported)
August 22, 2005
Progenics
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-23143
|
|
13-3379479
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
777
Old Saw Mill River Road, Tarrytown, New York
|
|
10591
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's
telephone number, including area code (914)
789-2800
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure
On
August
22, 2005, the Company announced additional positive data from a previously
completed pivotal phase 3 clinical trial
of its
investigational drug, methylnaltrexone (MNTX) for the treatment of
opioid-induced constipation in patients with advanced medical
illness.
Final
data analysis of the MNTX 301 study showed significant improvements in measures
of constipation distress, bowel movement difficulty and consistency, and global
impressions of clinical change. There were no increases in pain scores or opioid
withdrawal symptoms in any treatment group. At both doses of MNTX tested, all
prospectively defined secondary endpoints exhibited statistically significant
differences compared to placebo. A copy of the press release is attached hereto
as Exhibit 99.1 and the information contained therein is incorporated by
reference into this Item 7.01 of this Current Report on Form 8-K.
The
information furnished pursuant to Item 7.01 in this Form 8-K shall not be deemed
to be “filed” for the purposes of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that Section, unless we
specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake
no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 7.01 in this Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(c)
Exhibits
Exhibit
No. Description
99.1
Press
Release dated August 22, 2005
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/
ROBERT A.
MCKINNEY
Robert A. McKinney
Chief
Financial Officer, Vice President,
Finance
and Operations and Treasurer
Date:
August 24, 2005